There have been various studies conducted to prove that the intake of Canagliflozin is likely to reduce the risk of cardiovascular and kidney outcome especially in the person who are suffering from type 2 diabetes. Therefore, the main aim and objective of such studies are to calculate and understand the relative risk and absolute risk that is likely to be related to the effects of this abovementioned medicine. Therefore, in order to conduct this study a post hoc analysis of the Canagliflozin Cardiovascular Assessment study is conducted. The study involves participants from different countries and hence, an aim is made to ensure that the people who have been included in this study are all suffering from type 2 diabetes. The results highlighted that 98 percent had a baseline eGFR and UACR data. Hence, in the end, this was proved that the abovementioned medicine is very beneficial for maintaining health.
Ref art: https://www.ajkd.org/article/S0272-6386(20)30923-9/fulltext
